CDK Inhibition Reverses Acquired 5-Fluorouracil Resistance in Hepatocellular Carcinoma Cells

Dis Markers. 2022 Mar 11:2022:6907057. doi: 10.1155/2022/6907057. eCollection 2022.

Abstract

Background: 5-Fluorouracil (5-FU) has been widely applied in treating cancers. However, its usage is largely limited in hepatocellular carcinoma (HCC), due to acquired resistance. Here, we aim to identify target proteins and investigate their roles in 5-FU sensitivity of HCC cells.

Methods: Mass spectrometry (MS) proteomics was performed on 5-FU-resistant cell line (BEL7402/5-FU) and its parental cell line (BEL7402) with 5-FU treatment. In order to identify potential targets, we compared the proteomics between two cell line groups and used bioinformatics tools to select hub proteins from all differentially expressed proteins.

Results: We finally focused on a group of cell cycle-related kinases (CDKs). By CCK8 assay, we confirmed that the CDK inhibitor significantly decreased the IC50 of 5-FU-resistant cells.

Conclusions: Our study verified that CDK inhibition can reverse 5-FU resistance of HCC cells.

MeSH terms

  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / pathology
  • Cell Line
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Drug Resistance, Neoplasm*
  • Fluorouracil / pharmacology*
  • Humans
  • Liver Neoplasms / metabolism*
  • Liver Neoplasms / pathology
  • Mass Spectrometry
  • Protein Kinase Inhibitors
  • Proteomics

Substances

  • Protein Kinase Inhibitors
  • Cyclin-Dependent Kinases
  • Fluorouracil